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Another good reason  
to recommend low-dose aspirin 
Evidence shows that daily low-dose aspirin during 
pregnancy can safely lower the risk of preeclampsia  
and other adverse outcomes.
PRACTICE CHANGER 
Prescribe low-dose aspirin (eg, 81 mg/d) to 
pregnant women who are at high risk for pre-
eclampsia because it reduces the risk of this 
complication, as well as preterm birth and 
intrauterine growth restriction.1
StreNGtH OF reCOMMeNDAtiON
A: Based on a systematic review and meta-
analysis of 23 studies, including 21 random-
ized controlled trials. 
Henderson J, Whitlock E, O’Connor E, et al. Low-dose aspirin for pre-
vention of morbidity and mortality from preeclampsia: a systematic 
evidence review for the U.S. Preventive Services Task Force. Ann Intern 
Med. 2014;160:695-703.
ILLUSTRATIVE CASE
A 22-year-old G2p1 pregnant woman at 18 weeks 
gestation who has a history of preeclampsia 
comes to your office for a routine prenatal 
visit. on exam, her blood pressure continues 
to be in the 110s/60s, as it has been for sev-
eral visits. her history puts her at risk of de-
veloping preeclampsia again, and you wonder 
if anything can be done to prevent this from 
happening.
The incidence of preeclampsia, which occurs in 2% to 8% of pregnancies worldwide and 3.4% of pregnancies 
in the United States, appears to be steadily 
increasing.2,3 Preeclampsia is defined as 
new-onset hypertension at >20 weeks gesta-
tion, plus proteinuria, thrombocytopenia, 
renal insufficiency, impaired liver function, 
pulmonary edema, and/or cerebral or visual 
symptoms.4 The condition is associated with 
several adverse maternal and fetal outcomes, 
including eclampsia, abruption, intrauterine 
growth restriction (IUGR), preterm birth, still-
birth, and maternal death.2,4 Risk factors for 
preeclampsia include previous preeclampsia, 
maternal age ≥40 years, chronic medical con-
ditions, and multi-fetal pregnancy.5 
The only effective treatment for pre-
eclampsia is delivery.4 Given the lack of 
other treatments, strategies for preventing 
preeclampsia would be highly valuable. 
In 1996, the US Preventive Services Task 
Force (USPSTF) addressed this issue and con-
cluded that there was insufficient evidence to 
recommend for or against using aspirin to 
prevent preeclampsia.6 More recently, Hen-
derson et al1 conducted a systematic review 
and meta-analysis to support the USPSTF in a 
revision of its earlier recommendation.
STUDY SUMMARY
Aspirin use lowers risk of preeclampsia 
and preterm birth
Henderson et al1 evaluated the impact of low-
dose aspirin on maternal and fetal outcomes 
among pregnant women at risk for pre-
eclampsia. The review of 23 studies included 
21 randomized placebo-controlled trials 
that evaluated 24,666 patients. Slightly more 
than half of the studies that evaluated mater-
nal and fetal health benefits were graded as 
good-quality, and 67% of those that evalu-
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ated maternal, perinatal, and developmental 
harms were rated good-quality. 
Most women were white and ages 20 to 
33 years. Aspirin doses ranged from 60 mg/d 
to 150 mg/d; most studies used 60 mg/d or 
100 mg/d. Aspirin was initiated between 12 to 
36 weeks gestation, with 9 trials initiating as-
pirin before 16 weeks. In most trials, aspirin 
was continued until delivery. 
Among women at high preeclampsia risk 
(10 studies), the pooled relative risk (RR) for 
perinatal death was 0.81 (95% confidence 
interval [CI], 0.65-1.01) for low-dose aspirin 
compared to placebo. However, this finding 
was not statistically significant (P=.78). 
Among women who received low-dose 
aspirin, researchers noted a 14% risk reduc-
tion for preterm birth (RR=0.86; 95% CI, 
0.76-0.98); a 20% risk reduction for IUGR 
(RR=0.80; 95% CI, 0.65-0.99), and a 24% risk 
reduction for preeclampsia (RR=0.76; 95% 
CI, 0.62-0.95). The absolute risk reduction for 
preeclampsia was estimated to be 2% to 5%. 
While the results for preterm birth, 
IUGR, and preeclampsia were statistically 
significant, the authors noted that these re-
sults could have been biased by small study 
effects (the tendency of smaller studies to re-
port positive findings, which in turn can skew 
the results of a meta-analysis based primarily 
on such studies). The timing and dosage of 
aspirin had no significant effect on outcomes. 
There was no evidence of increased mater-
nal postpartum hemorrhage with aspirin use 
(RR=1.02; 95% CI, 0.96-1.09). Aspirin use did not 
seem to increase perinatal mortality among all 
risk levels (RR=0.92; 95% CI, 0.76-1.11; P=.65). 
No differences were noted in the toddlers’ de-
velopment at 18 months. 
WHAT’S NEW
Low-dose aspirin use  
is now recommended
The 1996 USPSTF recommendation con-
cluded that there was insufficient evidence 
to recommend aspirin use for preventing 
preeclampsia. This systematic review and 
meta-analysis, along with findings from a 
2007 Cochrane review7 and a meta-analysis 
from the PARIS Collaborative Group,8 pro-
vide good-quality evidence that aspirin re-
duces negative maternal and fetal outcomes 
associated with preeclampsia. In 2014, the 
USPSTF cited this evidence when it decid-
ed to recommend using low-dose aspirin 
(81 mg/d) to prevent preeclampsia in women 
who are at high risk for preeclampsia (Grade 
B).9 (For more on the USPSTF, see “Catching 
up on the latest USPSTF recommendations,” 
on page 296.)
CAVEATS
Much of the data 
came from small studies
A substantial portion of the data in this sys-
tematic review and meta-analysis came from 
small studies with positive findings. Because 
small studies with null findings tend to not 
be published, there is concern that the re-
sults reported by Henderson et al1 may be 
somewhat biased, and that future studies 
may push the overall observed effect toward 
a null finding. 
Also, the criteria used to define “high 
risk” for preeclampsia varied by study, so 
it’s unclear which groups of women would 
benefit most from aspirin use during preg-
nancy. Finally, there is a lack of high-qual-
ity data on the effects of aspirin use during 
pregnancy on long-term outcomes in chil-
dren. Despite these caveats, the cumulative 
evidence strongly points to greater benefit 
than harm.
CHALLENGES TO IMPLEMENTATION
you need to determine 
which patients are at highest risk 
The principle challenge lies in identify-
ing which patients are at high risk for pre-
eclampsia, and thus, will likely benefit from 
this intervention. This systematic review and 
meta-analysis used a large variety of risk fac-
tors to determine whether a woman was high 
risk. A 2013 American College of Obstetricians 
and Gynecologists Task Force on Hypertension 
in Pregnancy report defined high-risk as wom-
en with a history of preeclampsia in more than 
one previous pregnancy or women with a pre-
vious preterm delivery due to preeclampsia.4 
The updated USPSTF recommenda-
tion suggests that women be considered high 
researchers  
found no  
evidence  
of increased  
maternal  
postpartum 
hemorrhage 
with aspirin use.
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risk if they have any of the following: 1) pre-
vious preeclampsia, 2) multifetal gestation, 
3) chronic hypertension, 4) diabetes, 5) renal 
disease, or 6) autoimmune disease.9 We con-
sider both sets of criteria reasonable for iden-
tifying women who may benefit from low-dose 
aspirin during pregnancy.                            JFP
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